In another sign of recovery in digital health investing, Omada Health has priced an initial public offering (IPO) of $19 per ...

The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

It is the first fundraising effort at Neuralink since its $280 million Series D round in 2023 and brings the company's total ...

Added to that, 23andMe suffered a massive data breach in 2023 that resulted in information from about 7 million people being ...

The tantalising development has been reported by researchers at the Peter Doherty Institute for Infection and Immunity in ...

"Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor ...

Citylabs 4.0, now open in the heart of Manchester’s Knowledge Quarter on the Oxford Road Corridor, was built with exactly ...

The cash-based acquisition – the financial terms of which are not being disclosed – will expand Hims & Hers' presence in the ...

The FDA is moving at breakneck speed to roll out a generative artificial intelligence (AI) tool for speeding up regulatory ...

Zaynich is based on cefepime, a well-established beta-lactam antibiotic, combined with a novel beta-lactamase inhibitor ...

Meanwhile, the MHRA has also warned all people seeking treatment with the so-called "skinny jabs" to beware of counterfeit ...